Literature DB >> 9548425

Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement.

L L Hansen1, J Andersen, J Overgaard, T A Kruse.   

Abstract

In order to establish a large panel of normal and tumour DNA from primary breast cancer patients, we looked for a source of easily accessible, good quality breast tumour DNA. Following routine hormone receptor analysis at the hospital the leftover pellets contained the nuclei from the tumour tissue. We collected 670 pellets over a period of 2 1/4 years and isolated a large amount of DNA (on average 400 microg per pellet). To control the quality of this tumour DNA, we analysed 41 pellets and matching normal DNA for loss of heterozygosity (LOH), with 11 microsatellite markers along chromosome 17. This chromosome is well described for breast cancer. LOH is a sensitive method, requiring good quality and pure tumour DNA. Contamination with normal DNA will blur the results. We found a high rate of LOH, ranging from 33 to 74%, which is in agreement with other reports, and therefore recommend this rich source of breast tumour DNA for molecular biological analysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9548425     DOI: 10.1111/j.1699-0463.1998.tb01359.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  8 in total

1.  Chromosome 1q25.3 copy number alterations in primary breast cancers detected by multiplex ligation-dependent probe amplification and allelic imbalance assays and its comparison with fluorescent in situ hybridization assays.

Authors:  Emilia Wiechec; Jens Overgaard; Eigil Kjeldsen; Lise Lotte Hansen
Journal:  Cell Oncol (Dordr)       Date:  2012-12-18       Impact factor: 6.730

2.  Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM.

Authors:  Lasse S Kristensen; Tomasz K Wojdacz; Britta B Thestrup; Carsten Wiuf; Henrik Hager; Lise Lotte Hansen
Journal:  BMC Cancer       Date:  2009-12-21       Impact factor: 4.430

3.  A simple way to evaluate self-designed probes for tumor specific Multiplex Ligation-dependent Probe Amplification (MLPA).

Authors:  Kristina Pedersen; Emilia Wiechec; Bo E Madsen; Jens Overgaard; Lise Lotte Hansen
Journal:  BMC Res Notes       Date:  2010-06-26

4.  Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events.

Authors:  Tomasz K Wojdacz; Britta B Thestrup; Jens Overgaard; Lise Lotte Hansen
Journal:  Diagn Pathol       Date:  2011-11-30       Impact factor: 2.644

5.  Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing.

Authors:  Lasse Sommer Kristensen; Marianne Bach Treppendahl; Fazila Asmar; Mia Seremet Girkov; Helene Myrtue Nielsen; Tina Ellegaard Kjeldsen; Elisabeth Ralfkiaer; Lise Lotte Hansen; Kirsten Grønbæk
Journal:  Sci Rep       Date:  2013-09-27       Impact factor: 4.379

6.  Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer.

Authors:  Lasse Sommer Kristensen; Tina Ellegaard Kjeldsen; Henrik Hager; Lise Lotte Hansen
Journal:  BMC Cancer       Date:  2012-11-23       Impact factor: 4.430

7.  Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer.

Authors:  Bo Eskerod Madsen; Eliana Marisa Ramos; Mathieu Boulard; Katarzyna Duda; Jens Overgaard; Marianne Nordsmark; Carsten Wiuf; Lise Lotte Hansen
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

8.  Identification and characterization of locus-specific methylation patterns within novel loci undergoing hypermethylation during breast cancer pathogenesis.

Authors:  Tomasz K Wojdacz; Johanne A Windeløv; Britta B Thestrup; Tine E Damsgaard; Jens Overgaard; Lise Hansen
Journal:  Breast Cancer Res       Date:  2014-02-03       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.